FeedbackSummary of changes to recommendations as included in the second edition of the Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014
⁴⁶ Status: Removed (the recommendation has been superseded and is no longer relevant); Copied (the recommendation remains valid and is retained unchanged); Edited (There is no change in the evidence or in the intention of the recommendation, but the precise wording has been edited); Updated (a new evidence synthesis was conducted with review by the GDG with a full evidence-to-decision procedure); Developed de novo (a new topic, subgroup or intervention has been covered with a new evidence synthesis and a full evidence-to-decision procedure by the GDG)
⁴⁷ Defined as countries, subnational administrative units, or selected facilities, where the HIV prevalence among adult pregnant women is ≥1% or among TB patients is ≥5% in the 2014 Guidance for national tuberculosis programmes on the management of tuberculosis in children (second edition) (8).
⁴⁸ WHO does not intend to establish thresholds for low, moderate or high levels of prevalence of isoniazid resistance: NTPs will establish definitions for their own countries.
⁴⁹ Twice-weekly dosing is totally not recommended. See Guidelines for treatment of tuberculosis, fourth edition. Geneva: World Health Organization; 2010 (http://www.who.int/tb/publications/2010/9789241547833/ en/).
⁵⁰ The Global Advisory Committee on Vaccine Safety (GACVS) does not use the GRADE methodology for evaluating the quality of evidence; the BCG-related recommendations will therefore remain ungraded.
⁵¹ In ages two years and above.
⁵² In ages 13 and above.